The Cancer Prevention and Control Program (CPCP) is a productive and interactive multi-disciplinary team of 19 investigators, including 17 Full and two Associate Qunior mentored) Members drawn from 7 academic departments. The goal of the CPCP is to conduct innovative and high impact research in childhood cancer prevention and control through an integrated program encompassing outcomes and intervention research. Using institutional and national CPCP-led research resources consisting of the St. Jude Lifetime (SJLIFE) cohort, the Childhood Cancer Survivor Study (CCSS) cohort, and the St. Jude Consortium for Pediatric Intervention Research (CPIR), program members are conducting cancer survivorship-based research to describe the occurrence and pathogenesis of physiological and psychological long-term outcomes associated with the diagnosis and treatment of cancer during childhood and adolescence. A central theme of the CPCP is to translate findings from clinical and observational research into clinical practice or intervention trials designed to prevent or ameliorate the acute and long-term morbidity of treatment and improve quality of life. To. this end, the Program is organized around three principal areas of Research Emphasis: (1) Identification of High-Risk Groups and Insights into the Mechanisms of Treatment-related Outcomes. (2) Translation of Observational Research into Clinical Practice. (3) Translation of Observational Research into Intervention Trials Insights The CPCP relies heavily upon the Cancer Center's Biostatistics, Molecular Therapeutic Clinical Trials, and Hartwell Center shared resources. CPCP members are actively engaged in numerous protocol-specific collaborations with other Cancer Center programs. The CPCP membership is supported by $8.0 million in cancer-related funding ($7.9 million peer-reviewed; $0.1 million non-peer reviewed) and has published 406 papers of which 27% (n=110/406) were intraprogrammatic and 26% (n=104/406) were interprogrammatic.

Public Health Relevance

Almost 80% of U.S. children with cancer now survive beyond 5 years from diagnosis. These improved outcomes have resulted in a growing population of childhood cancer survivors, now estimated to number more than 370,000. This population is at increased risk for a variety of health problems. CPCP investigators are conducting research to further define the occurrence of, and risk factors for; these adverse late outcomes in order to develop intervention approaches that improve the quality of life of childhood cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-39
Application #
9439719
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Ma, Xiaotu; Liu, Yu; Liu, Yanling et al. (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371-376
Broniscer, Alberto; Jia, Sujuan; Mandrell, Belinda et al. (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 65:e27035

Showing the most recent 10 out of 6764 publications